Introduction
============

Bipolar disorder (BD) is a severe mental disorder characterized by recurrent manic and depressive episodes with a lifetime prevalence \~1%.^[@bib1],\ [@bib2]^ Epidemiological studies have consistently indicated significant contribution of genetic factors to the etiology of BD, and its heritability (broad-sense heritability that considers both the additive and non-additive genetic factors) calculated from the concordance rates in monozygotic and dizygotic twins is \~85%.^[@bib3]^ Because of this high heritability a number of genetic studies for BD have been conducted. However, linkage studies using family samples could not robustly identify causative genes.^[@bib4]^ More recently genome-wide association studies (GWAS) have identified single-nucleotide polymorphisms certainly associated with BD in several genes such as *CACNA1C* encoding a plasma membrane L-type Ca^2+^ channel,^[@bib5],\ [@bib6]^ whereas the effect size of each robustly associated single-nucleotide polymorphism is tiny (typically only increases the risk by 1.1--1.2 fold) and a large part of the disease heritability cannot be explained even if hundreds of thousands of weakly associated common single-nucleotide polymorphisms are considered.^[@bib7]^ This phenomenon is termed as the 'missing heritability\', and potential roles of rare variants that have not been investigated in GWAS are drawing increasing attention.

As one of the proofs for the hypothesis that rare variants could have a significant role in the genetic architecture of BD, recent whole-genome sequencing of 200 individuals from 41 bipolar families showed the role of rare transmitted variants in neuronal excitability related genes including those encoding calcium channels.^[@bib8]^ In addition to rare transmitted variants, *de novo* (newly arising) mutations could be another class of genetic variation that explains a part of the missing heritability (note that *de novo* mutations explain a part of 'broad-sense\' heritability while these are not inherited^[@bib9]^). Indeed, recent studies have implicated contribution of *de novo* copy-number variations (CNVs) to the risk for BD,^[@bib10],\ [@bib11]^ particularly patients with an early onset.^[@bib10]^ In addition to CNVs, *de novo* point mutations, whose frequency increases as paternal age advances,^[@bib12]^ could have an important role in BD, because it has been well known that an older age of the father increases risk for BD in the offspring.^[@bib13],\ [@bib14]^ However, to our knowledge there has been no study reporting results of comprehensive analysis of *de novo* point mutations in BD, whereas their significant contribution to the genetic architectures of various neuropsychiatric disorders including autism spectrum disorder (ASD)^[@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21]^ and schizophrenia^[@bib22],\ [@bib23],\ [@bib24],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28]^ has been consistently reported in recent whole-exome sequencing (WES) studies that analyze all coding exons in the human genome.

To address the question whether *de novo* point mutations contribute to the genetic architecture of BD, here we performed, to the best of our knowledge, the first trio-based WES study for BD by analyzing 237 exomes.

Materials and methods
=====================

Studied subjects
----------------

We used DNA samples from 79 trios with a BD proband (56 with bipolar I disorder (BDI) and 23 with bipolar II disorder (BDII)) and unaffected parents. All the probands were diagnosed with BDI or BDII based on the DSM (Diagnostic and Statistical Manual of Mental Disorders) IV criteria by trained psychiatrists. All the parents were screened for mental disorders by structured interview using M.I.N.I. (Mini International Neuropsychiatric Interview).^[@bib29]^ See [Supplementary Information](#sup1){ref-type="supplementary-material"} for more detailed information. The study was approved by the First Committee of Research Ethics of RIKEN Wako Institute and the Institutional Review Board of Yamaguchi University Hospital.

Exome sequencing, data processing, variant calling and identification of *de novo* mutations
--------------------------------------------------------------------------------------------

Genomic DNA from either peripheral blood or saliva was subjected to target capturing using the SureSelect^XT^ Human All Exon kits V4, V5 or V5 + mitochondria (Agilent Technologies, Santa Clara, CA; detailed information is available in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). WES was performed by using either the HiSeq2000 or HiSeq2500 (Illumina, San Diego, CA, USA) with paired-end 101 bp reads. Generated sequence data (fastq files) were processed by using the pipeline with BWA-MEM^[@bib30]^ (version 0.7.5a), SAMtools,^[@bib31]^ Picard (version 1.92, <http://picard.sourceforge.net/>) and GATK^[@bib32]^ (version 2.6--4). Variant calls were made by using the GATK best practices recommendations.^[@bib33]^ Identified candidates for *de novo* mutations were subjected to validation experiments by amplification using PCR followed by standard Sanger sequencing. *De novo* CNVs were identified by using exome hidden Markov model (XHMM)^[@bib34],\ [@bib35],\ [@bib36]^ and copy-number inference from exome reads (CoNIFER)^[@bib37]^ and validated by comparative genome hybridization arrays. See [Supplementary Information](#sup1){ref-type="supplementary-material"} for more detailed information.

Analyses of genes hit by *de novo* mutations using RVIS
-------------------------------------------------------

We assigned Residual Variation Intolerance Score (RVIS) representing 'gene intolerance\' to protein-altering genetic variation in general population to each gene hit by a *de novo* mutation using Dataset 2 of Petrovski *et al.*^[@bib38]^ Among the 70 genes with *de novo* mutations in our BD cohort, 66 genes were assigned for RVIS and used for the subsequent analyses. In Petrovski *et al.*,^[@bib38]^ the hypothesized probability that a *de novo* mutation hit the first quartile of the most intolerant genes was calculated as 38% considering gene sizes. This was because,

We obtained the data of coding length for each gene assigned for RVIS using UCSC Table Browser (<https://genome.ucsc.edu/cgi-bin/hgTables>) and calculated that

Therefore if a mutation is randomly generated, the probabilities to hit the first percentile and the first quartile of the intolerant genes are 4% and 38%, respectively. On the basis of these hypothesized probabilities (4% for the first percentile and 38% for the first quartile), we evaluated whether the first percentile and the quartile of 'intolerant genes\' are enriched among the genes hit by three types of mutations (that is, loss-of-function (LOF), protein-altering and synonymous) in our cohort using one-tailed binominal exact test. For example, there are 53 genes with a *de novo* protein-altering mutation in BD for which RVIS is available. If 53 mutations are randomly generated, the expected number of first percentile of intolerant genes hit by a protein-altering mutations is 53 × 0.04=2.1, whereas we observed that six genes were among the first percentile of the intolerant genes in the real data set for BD. On the basis of these observations, we performed one-tailed binominal exact test with the following numbers; the number of success (*x*)=6, the number of trials (*n*)=53 and the hypothesized probability of success (*p*)=0.04. The corresponding commend for R software we used for the analysis was *binom.test(x=6, n=53, p=0.04, alternative=\"greater\")*.

Enrichment analysis of LOF and protein-altering *de novo* mutations in case subjects
------------------------------------------------------------------------------------

Global enrichment of *de novo* LOF and protein-altering mutations in case subjects were examined by one-tailed Fisher\'s exact test using the reported data of 1911 unaffected siblings.^[@bib39]^ For an extended analysis, published data on schizoaffective disorder (SAD)^[@bib24],\ [@bib27]^ was combined with the current data set of BD. Details are described in [Supplementary Information](#sup1){ref-type="supplementary-material"}.

Procedures for gene ontology (GO) enrichment analysis of *de novo* LOF and protein-altering mutations and other analyses are detailed in [Supplementary Information](#sup1){ref-type="supplementary-material"}.

Results
=======

Identification of *de novo* point mutations in bipolar disorder
---------------------------------------------------------------

We performed WES of 237 DNA samples from a cohort consisting of 79 probands affected with BD and their parents without major psychoses (that is, BD, schizophrenia and SAD, [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). On average 92.5% of the targeted exome regions were covered by 20 or more reads at the individual level. At the trio level, on average 88.9% of the targets were covered by 20 or more reads in all three members ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Among the 79 trios, we identified 71 *de novo* point mutations (single-nucleotide variations (SNVs) and short insertion/deletions (indels)) in 70 genes, which were validated by Sanger sequencing ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). As two missense mutations in *DOCK10* were identified in the same individual on the same sequencing reads with an interval of four bases, we considered these mutations as a single missense mutation event (thus there are 70 *de novo* events). These 70 *de novo* events comprise of 64 SNVs (including the composite mutation noted above) and six indels, including four nonsense mutations, one canonical splice site mutation, 45 missense mutations, 14 synonymous mutations, four frameshift indels (of which two mutations directly introduce a stop codon) and two inframe indels. The number of *de novo* mutations in each proband ranged from zero to four. Forty-two probands carried one or more *de novo* mutations. Per-individual number of *de novo* mutations was 0.89, which is similar to those reported in the largest family-based WES studies for ASD^[@bib20]^ (0.94 for ASD and 0.84 for unaffected siblings, based on re-annotated data using our analytical pipelines) and schizophrenia^[@bib26]^ (0.90 for schizophrenia) to date.

Identification of *de novo* CNV from exome sequencing data
----------------------------------------------------------

We next analyzed CNVs using our WES data. For this purpose we used two software, XHMM^[@bib34],\ [@bib35],\ [@bib36]^ and CoNIFER,^[@bib37]^ both of which were specifically developed to detect CNVs from WES data sets. We identified a *de novo* deletion of approximately 0.2 Mbp at 3q29 including *ATP13A3*, *TMEM44*, *LSG1* and *FAM43A* (approximated position in hg19=chr3: 194.2 - 194.4M), which was confirmed by comparative genome hybridization arrays ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). This *de novo* deletion is located at \~1.3 Mbp upstream of the known 3q29 deletion syndrome locus, whose nominal association with BD was recently reported.^[@bib40]^ In addition to direct disruption of the genes included in the CNV region, this deletion may have some regulatory impact on genes in the 3q29 deletion syndrome locus.

*De novo* LOF and protein-altering mutations in BD preferentially hit intolerant genes
--------------------------------------------------------------------------------------

We next analyzed properties of genes hit by *de novo* mutations in BD in the context of 'gene intolerance\'. Recently Petrovski *et al.*^[@bib38]^ developed RVIS, a scoring system to assess intolerance of individual genes to protein-altering variants based on large-scale WES data of general population. By using RVIS it has been demonstrated that genes hit by *de novo* LOF (nonsense, splice site and frameshift; all of these are expected to totally disrupt the protein sequence) and protein-altering (that is, LOF, missense and inframe indel) mutations in ASD and schizophrenia are enriched for the first quartile (25 percentile) of intolerant genes,^[@bib28],\ [@bib38]^ and rare transmitted LOF variants in the first percentile of highly intolerant genes are enriched in ASD probands when compared with their healthy siblings.^[@bib41]^

Among 70 genes hit by *de novo* mutations in BD, 66 genes were assigned for RVIS. When we analyzed gene intolerance by classifying mutations according to their predicted functionality (that is, LOF, protein-altering or synonymous), we found that genes with *de novo* LOF mutations or protein-altering mutations are significantly enriched for the first percentile of intolerant genes ([Figures 1a](#fig1){ref-type="fig"}, *P*=4.5 × 10^−3^ for LOF and *P*=0.019 for any protein-altering mutations, one-tailed binominal exact test, see Materials and Methods for details), whereas there was no enrichment in genes with synonymous mutations (*P*=1). A similar trend was observed when we analyzed for the first quartile of intolerant genes (*P*=0.079 for LOF, *P*=0.067 for protein-altering and *P*=0.79 for synonymous mutations). These findings equivalent to those for ASD and schizophrenia, for which roles of *de novo* mutations are established, suggest contribution of *de novo* mutations, particularly *de novo* LOF and protein-altering mutations in intolerant genes, to the genetic etiology of BD.

According to these results and previous WES studies for ASD and schizophrenia mostly reporting global enrichment of *de novo* LOF and protein-altering mutations in case subjects,^[@bib20],\ [@bib21],\ [@bib22],\ [@bib24],\ [@bib25],\ [@bib27],\ [@bib28],\ [@bib42]^ we also tested whether there is global excess of these mutations in BD. For this purpose, we compared the numbers of *de novo* LOF or protein-altering mutations and *de novo* synonymous mutations between our BD probands and a large cohort of control subjects (1911 unaffected siblings in Iossifov *et al.*^[@bib20]^), because this method using synonymous mutations as an internal control should be resistant to potential artifacts caused by comparison of data from different studies. There was no statistically significant enrichment of *de novo* LOF and protein-altering mutations in BD (odds ratio (OR)=1.48, *P*=0.244, for LOF mutations, OR=1.30, *P*=0.233 for protein-altering mutations, one-tailed Fisher\'s exact test, [Figure 1b](#fig1){ref-type="fig"}).

Considering relationship between *de novo* mutations and clinical phenotypes in our BD cohort, we observed that there is significant difference in age of onset between the probands carrying one or more *de novo* protein-altering mutations and the probands with no protein-altering mutation ([Figure 1c](#fig1){ref-type="fig"}, two-tailed Student\'s *t*-test, *P*=0.013, average age of onset±s.d.=21.6±6.1 in mutation carriers and 25.9±8.8 in non-carriers), while there was no significant difference in age of ascertainment between these two groups.

Global enrichment of *de novo* LOF and protein-altering mutations in BDI and SAD
--------------------------------------------------------------------------------

As a moderate sample size in our cohort limit the statistical power, we next performed a joint analysis by combining our data set and the published data for patients with SAD^[@bib43]^ characterized by both the mood and psychotic symptoms and shares genetic background with BD^[@bib44]^ (no. of trios=143; 79 BD from our cohort, 63 SAD from Xu *et al.,*^[@bib24]^ and one SAD from MaCarthy *et al.*^[@bib27]^). In the analysis comparing this combined group of BD and SAD to controls (1911 unaffected siblings in Iossifov *et al.*^[@bib20]^ as described above), we observed a trend toward enrichment of *de novo* LOF and protein-altering mutations (*P*=0.085, OR=1.73 for LOF mutations, *P*=0.073, OR=1.47 for protein-altering mutations, [Figure 1b](#fig1){ref-type="fig"}). In addition, when we focused on the severer group, patients with BDI or SAD, there was statistically significant enrichment of *de novo* LOF and protein-altering mutations in the case group (*P*=0.030, OR=2.30 for LOF mutations, *P*=0.021, OR=1.87 for protein-altering mutations, [Figure 1b](#fig1){ref-type="fig"}), whereas further large-scale studies should be required to conclude enrichment of these mutations.

GO enrichment analysis of the genes hit by *de novo* protein-altering mutations
-------------------------------------------------------------------------------

On the basis of the results of our analyses showing global enrichment of *de novo* protein-altering mutations in BDI and SAD, we next exploratory investigated whether there are specific GO terms overrepresented among the genes hit by these mutations in the combined group of BDI and SAD.

We first performed a GO enrichment analysis with the Database for Annotation, Visualization and Integrated Discovery (DAVID, v6.7)^[@bib45],\ [@bib46]^ using the list of genes hit by *de novo* protein-altering mutations in BDI and SAD as an input (no. of genes=75, [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). There was no GO term with significant enrichment after performing correction for multiple testing. Non-significant trend of enrichment was found for nine GO terms including 'calcium ion binding (GO:0005509)\', 'serine-type peptidase activity (GO:0008236)\' and 'tissue morphogenesis (GO:0048729)\' ([Figure 2a](#fig2){ref-type="fig"}). To test whether the suggestive enrichment of these terms are noteworthy, we performed a simulation analysis by randomly selecting 75 *de novo* protein-altering mutations, equal to the number of mutations in BDI and SAD, from the list of *de novo* protein-altering mutations reported in control subjects^[@bib20]^ 10 000 times ([Figure 2b](#fig2){ref-type="fig"}, see [Supplementary Information](#sup1){ref-type="supplementary-material"} for details). We counted how many times nominally significant enrichment of a given GO term was observed, and the probability to see significant enrichment among 10 000 trials was considered as the *P*-value. If the enrichment observed in our DAVID analysis is explained by artifacts due to use of genes harboring *de novo* mutations as an input (for example, the input genes should be biased toward large genes because such genes have higher chance to be hit by *de novo* mutations), significant enrichment should not be observed in this simulation analysis. Three GO terms showed non-significant results in the simulation analysis. We observed nominally significant enrichment (uncorrected *P*-value \<0.05 in the simulation analysis) of six GO terms; 'calcium ion binding (GO:0005509)\', 'tissue morphogenesis (GO:0048729)\', 'serine-type peptidase activity (GO:0008236)\', 'serine hydrolase activity (GO:0017171)\', 'embryonic morphogenesis (GO:0048598)\' and 'protein homodimerization activity (GO:0042803)\'. However, this enrichment was no more significant after the correction for multiple testing with the number of terms subjected to the simulation analysis, except for 'serine-type peptidase activity (GO:0008236)\' and 'serine hydrolase activity (GO:0017171)\'. Individual genes with a *de novo* protein-altering mutation included in each term are detailed in [Figure 2a](#fig2){ref-type="fig"}.

New candidate genes for bipolar disorder
----------------------------------------

The list of genes harboring *de novo* mutations in BD could help identification of promising new candidate genes for BD.

According to the 'ascertainment differentials\', the differences in the frequencies of each class of mutation in two populations^[@bib20],\ [@bib47]^ calculated from per-individual rates of *de novo* LOF or protein-altering mutations in our BD cohort and control subjects (1911 unaffected siblings in Iossifov *et al.*,^[@bib20]^ see [Supplementary Information](#sup1){ref-type="supplementary-material"} for details), roughly 22% and 9% of *de novo* LOF and protein-altering mutations in BD could contribute to the diagnosis of BD, respectively. This indicates that genes with *de novo* LOF mutations should be particularly enriched for genuine disease susceptibility genes. Among nine genes with a *de novo* LOF mutation, we found enrichment of genes highly intolerant to functional variation as described above. These genes hit by a LOF mutation despite their high intolerance, *EHD1*, *KLF4*, *KMT2C*, *MACF1*, *UNC13B* and *XPO4* ([Table 2](#tbl2){ref-type="table"}), should be good candidates for disease susceptibility genes.

Previous studies have pointed out genes hit by multiple *de novo* protein-altering mutations, particularly LOF mutations, are highly likely to be genuine disease genes.^[@bib48],\ [@bib49],\ [@bib50]^ Although there was no gene with two or more *de novo* protein-altering mutations in our BD cohort or the combined group of BD and SAD, when we compared the list of genes hit by *de novo* protein-altering mutations in BD with the list for schizophrenia (excluding known cases of SAD) we found six genes hit by *de novo* protein-altering mutations in BD and also in schizophrenia (*BZRAP1*, *DNAH9*, *GLI3*, *KMT2C*, *LCT* and *MACF1*, [Table 2](#tbl2){ref-type="table"}). Although the P-values for observed numbers of *de novo* protein-altering mutations in these genes (calculated by the procedures described in Samocha *et al.,*^[@bib49]^ see [Supplementary Information](#sup1){ref-type="supplementary-material"} for details) do not reach to the exome-wide significance threshold (*P*=2.5 × 10^−6^, considering the number of coding genes, [Table 2](#tbl2){ref-type="table"}), some of them could be good candidates for genes associated with BD and schizophrenia that share genetic risk factors.^[@bib51],\ [@bib52]^

Discussion
==========

In this study reporting results of the first trio-based WES for BD, we identified 71 *de novo* point mutations and one *de novo* CNV in 79 probands. By exploring the properties of *de novo* mutations and genes hit by these mutations in BD, we observed significant enrichment of *de novo* LOF mutations hitting genes highly intolerant to functional variants as well as a trend toward global excess of *de novo* LOF and protein-altering mutations. In the joint analysis combining our data of BD and the data of SAD in published studies, we observed global enrichment of LOF and protein-altering mutations in the severer group of patients consisting of BDI and SAD, implicating contribution of these mutations to the genetic etiology. Our analysis of relationship between clinical phenotypes and *de novo* protein-altering mutations revealed significantly earlier age at onset in probands with one or more such mutations than non-carriers. This observation is in line with a previous study reporting stronger association of *de novo* CNVs with early-onset BD.^[@bib10]^ Although further large-scale studies are required to prove the pathogenic role of *de novo* mutations in BD, given the moderate sample size and statistical significance in this study, our observations would be credible considering the fact that similar results have been reported for ASD and schizophrenia. *De novo* SNVs reportedly increase with advanced paternal age.^[@bib12]^ In a disease with constant prevalence rate despite reduced reproduction fitness, genetic risk factors are assumed to be constantly supplied as *de novo* mutations. Because the risk for BD is associated with advanced paternal age^[@bib13],\ [@bib14]^ and BD patients show reduced reproduction fitness,^[@bib53],\ [@bib54]^ albeit less so than in schizophrenia and ASD,^[@bib53]^ it is plausible that de novo SNVs have a role in etiology of BD.

In our GO enrichment analyses of genes hit by *de novo* protein-altering mutations in BDI and SAD, we identified nominal enrichment of six GO terms. Among them, enrichment of 'serine-type peptidase activity (GO:0008236)\' and 'serine hydrolase activity (GO:0017171)\' remained significant when we considered the number of terms subjected to our simulation analysis, suggesting potential involvement of this pathway in the pathophysiology of BD. In addition, identification of 'calcium ion binding (GO:0005509)\' as one of nominally enriched terms should be of interest, because this result is in line with findings in previous genetic, biochemical and pharmacological studies for BD. For instance, association of several voltage-dependent calcium channel genes such as *CACNA1C and CACNA1B* was reported in large-scale GWAS for BD.^[@bib5],\ [@bib55]^ A pathway analysis of GWAS data suggests enrichment of calcium channel-related pathways among the genes empirically associated with BD.^[@bib56]^ Studies of peripheral blood cells have consistently demonstrated altered intracellular calcium signaling in BD.^[@bib57],\ [@bib58]^ Lithium, the first-line therapeutic drug for BD, modulates inositol-mediated pathways^[@bib59]^ and thereby regulate calcium ion release from the endoplasmic reticulum.^[@bib60]^ When we performed a GO enrichment analysis using DAVID^[@bib45],\ [@bib46]^ by integrating the data of *de novo* protein-altering mutations in our study, common single-nucleotide polymorphisms associated with BD in a large-scale GWAS^[@bib5]^ and rare CNVs implicated in BD^[@bib40]^ (total no. of unique input genes=229, see [Supplementary Information](#sup1){ref-type="supplementary-material"} for details), 'calcium signaling pathway (hsa04020)\' was the only term significantly enriched after performing correction for multiple testing (*P*~corrected~=6.4 × 10^−3^, Bonferroni correction; note that significant enrichment of 'calcium signaling pathway (hsa04020)\' after correction was not observed when we submitted candidate genes from each study). This result of an integrative analysis indicates that various types of genetic evidence for BD could converge on the calcium signaling pathway.

When we looked at individual genes carrying a *de novo* mutation to search for promising candidate genes, we found that *KMT2C*, *MACF1* and *UNC13B* are hit by a *de novo* LOF mutation despite their extremely high intolerance to protein-altering variants^[@bib38]^ ([Table 1](#tbl1){ref-type="table"}). *KMT2C* (also known as *MLL3*) encodes a catalytic subunit of histone methyltransferase protein complex specifically mediating mono-, di- and tri-methylation of histone H3 at lysine 4 (H3K4). Identification of a *de novo* LOF mutation in this gene that is also hit by *de novo* protein-altering mutations in ASD and schizophrenia^[@bib17],\ [@bib21],\ [@bib26]^ could be in line with accumulating evidence pointing out important roles of chromatin regulator genes in neuropsychiatric disorders.^[@bib21],\ [@bib27],\ [@bib28],\ [@bib61],\ [@bib62]^ *MACF1* (also known as *ACF7*) encodes the microtubule actin cross-linking factor 1 protein that has an essential role in integration of microtubule dynamics.^[@bib63]^ This gene categorized as a 'calcium ion binding (GO:0005509)\' gene is involved in calcium-induced reorganization of the cytoskeleton.^[@bib64]^ Interestingly, binding of MACF1 to microtubules is regulated by GSK3β,^[@bib65]^ a key enzyme implicated in the mechanism of action of lithium.^[@bib66]^ *UNC13B* (also known as *MUNC13*) encodes a presynaptic protein with an essential role in synaptic vesicle priming. Although this gene is not classified as a 'calcium ion binding (GO:0005509)\' gene, UNC13B forms a complex with calmodulin, a calcium ion binding protein, and this complex regulates synaptic vesicle priming and synaptic efficacy in response to residual calcium ion signals,^[@bib67]^ further suggesting involvement of the calcium signaling pathway in the BD pathophysiology. Besides these three genes, *EHD1* could be another promising candidate gene in the context of possible relationship between BD and the calcium signaling pathway. This gene carrying a *de novo* LOF mutation in BD encodes a calcium binding protein involved in regulation of synaptic endocytosis and exocytosis.^[@bib68],\ [@bib69]^ In addition, our preliminary experiments indicate that the *de novo* frameshift mutation in *EHD1* at the last exon of this gene cause expression of the protein lacking EF-hand calcium binding domain by escaping nonsense-mediated mRNA decay ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). This truncated form of EHD1 protein may have a dominant negative effect. These four genes could be particularly good candidates for disease susceptibility genes for BD, and it would be worthwhile to subject these genes to target resequencing.^[@bib70]^

In summary, we performed the first trio-based WES study for BD and demonstrated potential roles of *de novo* protein-altering mutations and calcium-related genes in the disease etiology. These findings are in accordance with the results of previous WES studies for other neuropsychiatric disorders with reduced fecundity such as ASD and schizophrenia, and with the evidence from various types of studies for BD. Our results could provide important insights into the genetic architecture and biology of BD, and warrant further large-scale studies in order to understand the roles of *de novo* and rare mutations in BD more precisely, and to identify robust disease-associated genes/mutations with a large effect size.
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![Roles of *de novo* loss-of-function (LOF) and protein-altering mutations in bipolar disorder. (**a**) Proportion of the genes hit by different types of *de novo* mutations according to their gene intolerance. Gene intolerance to protein-altering variants in general population was assessed by using Residual Variation Intolerance Score (RVIS).^[@bib38]^ Black, \<1st percentile of intolerant genes; gray, 1--25th percentiles of intolerant genes; white, rest of the genes (25--100th percentiles). Dashed and solid red lines indicate expected proportion for the first percentile and the first quartile of intolerant genes considering gene sizes (4 and 38%, see Materials and Methods for detailed procedures). Enrichment *P*-values for the first percentile of intolerant genes calculated by one-tailed binominal tests are shown on the right side of the bars. (**b**) Enrichment analyses of *de novo* LOF and protein-altering mutations in case groups. Bars indicate statistical significance (log~10~ *P*-values) for enrichment of *de novo* LOF (black) and protein-altering (gray) mutations in each disease group. Enrichment was evaluated by comparing the numbers of *de novo* LOF or protein-altering mutations and synonymous mutations between each disease group, and controls (1911 unaffected siblings in Iossifov *et al.*^[@bib20]^) with one-tailed Fisher\'s exact test. Data for autism spectrum disorder (ASD) were shown as a reference.^[@bib20]^ Red dashed line indicates *P*=0.05. (**c**) Box plots of age of onset for bipolar disorder (BD) probands with or without protein-altering *de novo* mutations. Average ages of onset between the two groups were compared by two-tailed Student\'s *t*-test. Box plots of median values with hinges at the 25th and 75th percentiles and whiskers extending to the highest and lowest values are shown. BDI, bipolar I disorder; OR, odds ratio; SAD, schizoaffective disorder.](mp201669f1){#fig1}

![Gene ontology enrichment analysis of the genes hit by *de novo* protein-altering mutations. (**a**) Six gene ontology (GO) terms nominally enriched among the genes hit by *de novo* protein-altering mutations in the combined group of bipolar I disorder (BDI) and schizoaffective disorder (SAD). P_DAVID indicates *P*-values calculated by DAVID (The Database for Annotation, Visualization and Integrated Discovery)^[@bib45],\ [@bib46]^ (uncorrected raw P-values). P_Simulation indicates *P-*values calculated by a simulation analysis using the data of *de novo* protein-altering mutations in control subjects (1911 unaffected siblings in Iossifov *et al.*^[@bib20]^). For P_Simulation, both the raw *P*-values and *P*-values corrected for the number of terms subjected to the simulation analysis (\#=9, Bonferroni procedure) were noted. Boldface indicates genes with a *de novo* loss-of-function (LOF) mutation in bipolar disorder (BD). Genes with *de novo* mutations identified in SAD^[@bib24],\ [@bib27]^ are shown in parentheses. (**b**) Histograms represent the distribution of hit counts in the simulation analyses (10 000 iterations) for seven GO terms. Dotted lines indicate the observed hit counts (obs.) and the corresponding *P*-values.](mp201669f2){#fig2}

###### List of 71 *de novo* point mutations in 79 trios with BD probands

  *ID*    *BD type*  *Chromosome*   *Start position*    *Reference*   *Alternative*                  *Mutation type*                   *Gene symbol*   *Amino-acid change*[a](#t1-fn2){ref-type="fn"}
  ------ ----------- -------------- ------------------ ------------- --------------- ------------------------------------------------ --------------- ------------------------------------------------
  103         I      17             43192727                 G              A                            Missense                         *PLCD3*                         p.A515V
  105         I      4              3251006                  C              T                           Synonymous                       *MSANTD1*                         p.G19G
  106         I      2              128176049                T              G                            Missense                         *PROC*                           p.S9R
  107         I      1              171673653                C              T                            Missense                         *VAMP4*                         p.R140H
  107         I      X              21995301                 A              G                            Missense                          *SMS*                          p.K151R
  110         I      1              39735167                ---             C                      Frameshift insertion                   *MACF1*                         p.V266fs
  111         I      11             6653775                  C              T                            Missense                         *DCHS1*                         p.D990N
  115         I      3              197497100                G              A                            Missense                        *FYTTD1*                         p.S161N
  116         I      11             64621996                 C             ---        Frameshift deletion[b](#t1-fn3){ref-type="fn"}      *EHD1*                          p.V472X
  116         I      16             18820961                 T              C                            Missense                         *SMG1*                          p.Y3640C
  116         I      18             65179594                 C              T                            Missense                         *DSEL*                          p.G761D
  117         I      12             53565177                 C              T                            Missense                         *CSAD*                          p.R194H
  118         I      9              104341502                C              T                           Synonymous                       *GRIN3A*                         p.L969L
  118         I      14             23862939                 T              A                            Missense                         *MYH6*                          p.D955V
  119         I      11             124793786                T              C                            Missense                        *HEPACAM*                        p.D183G
  120         I      11             397415                  ---            CCA                      Inframe insertion                     *PKP3*                       p.S305delinsSH
  120         I      12             71978307                 C              T                           Synonymous                        *LGR5*                          p.Y839Y
  120         I      X              73811786                 G              A                            Missense                         *RLIM*                          p.S455F
  121         I      10             27459678                 C              T                            Missense                         *MASTL*                         p.S597F
  122         I      8              139164319                T              A                            Missense                        *FAM135B*                        p.D800V
  122         I      9              35403597                 G              A                          Splice site                       *UNC13B*                           ---
  122         I      11             6291989                  A              G                            Missense                         *CCKBR*                         p.D256G
  122         I      22             21989506                 G              C                            Missense                        *CCDC116*                        p.G385A
  123        II      18             58039428                 A              G                            Missense                         *MC4R*                           p.V52A
  127        II      4              187177191                C              T                            Missense                         *KLKB1*                         p.T512I
  130         I      15             51828860                 A              G                            Missense                         *DMXL2*                         p.L606S
  132         I      1              63284902                 C              A                           Synonymous                        *ATG4C*                         p.S207S
  134         I      2              197707468                A              C                           Synonymous                        *PGAP1*                         p.T869T
  134         I      16             847034                   C              T                            Missense                        *CHTF18*                         p.P1101L
  135         I      4              68688179                 C              T                            Missense                       *TMPRSS11D*                       p.R378Q
  135         I      12             121691252                G              A                            Missense                        *CAMKK2*                         p.R311C
  205         I      1              110280787                G              A                            Nonsense                         *GSTM3*                         p.R100X
  205         I      7              42017240                 C              T                            Missense                         *GLI3*                          p.V577I
  209        II      2              225662602                A              G                            Missense                        *DOCK10*                         p.S1531P
  209        II      2              225662607                T              C                            Missense                        *DOCK10*                         p.N1529S
  212        II      14             105957989                G              A                            Missense                       *C14orf80*                         p.V21M
  213        II      6              7182273                  C              G                           Synonymous                        *RREB1*                          p.P43P
  213        II      11             75591045                 G              A                            Nonsense                         *UVRAG*                         p.W131X
  214         I      17             56387403                ---            TCC                      Inframe insertion                    *BZRAP1*                     p.E1272delinsEE
  215         I      2              55544865                 C              T                            Missense                        *CCDC88A*                        p.R1146Q
  215         I      7              151859861                T              A                            Nonsense                         *KMT2C*                         p.K3601X
  215         I      10             73494079                 C              G                            Missense                         *CDH23*                         p.P1401R
  215         I      14             74567890                 G              C                            Missense                         *LIN52*                          p.E82Q
  217        II      13             21436873                 A              T                            Nonsense                         *XPO4*                          p.Y100X
  219         I      1              33558984                 C              T                            Missense                         *AZIN2*                         p.A185V
  219         I      9              110249695                C             ---                     Frameshift deletion                    *KLF4*                          p.S327fs
  220         I      2              223536557                C              A                            Missense                        *MOGAT1*                          p.T18K
  221         I      17             61889463                 A              T                            Missense                         *DDX42*                         p.N524Y
  223        II      7              150935311                C              T                           Synonymous                        *CHPF2*                         p.V621V
  301        II      5              16704730                 G              A                            Missense                         *MYO10*                         p.A756V
  303        II      9              100444622                A              C                            Missense                          *XPA*                          p.F255C
  311        II      1              11896118                 C              T                            Missense                         *CLCN6*                         p.H630Y
  311        II      11             47354513                 G              A                           Synonymous                       *MYBPC3*                         p.T1114T
  311        II      11             57970920                 T              G                            Missense                         *OR1S2*                         p.Q245P
  311        II      22             21336724                 T              C                            Missense                         *LZTR1*                          p.S22P
  312        II      6              143085951                C              T                            Missense                        *HIVEP2*                         p.A1835T
  312        II      19             54966705                 C              T                           Synonymous                        *LENG8*                         p.G328G
  314         I      6              90410529                 T              C                            Missense                         *MDN1*                          p.K2825R
  316        II      15             44092967                 T              C                           Synonymous                        *HYPK*                          p.S103S
  316        II      17             11738078                 A              G                            Missense                         *DNAH9*                         p.M3124V
  317         I      4              56726636                 G              C                            Missense                         *EXOC1*                          p.D62H
  317         I      10             5924978                  A              G                           Synonymous                       *ANKRD16*                        p.Y280Y
  319         I      15             67528983                 G              A                           Synonymous                        *AAGAB*                          p.Y83Y
  319         I      22             39627761                 G              A                            Missense                         *PDGFB*                         p.R108W
  321        II      1              165324728                C              G                           Synonymous                        *LMX1A*                          p.S23S
  321        II      1              209799134                C              T                            Missense                         *LAMB3*                         p.G612E
  321        II      6              151669922                C              T                           Synonymous                       *AKAP12*                         p.H132H
  321        II      19             16625364                 C              G                            Missense                       *C19orf44*                        p.L598V
  324         I      6              64401764                 A              C                            Missense                         *PHF3*                          p.K776T
  325         I      14             53513547                 A             ---        Frameshift deletion[b](#t1-fn3){ref-type="fn"}      *DDHD1*                         p.L881X
  325         I      20             39794889                 C              T                            Missense                         *PLCG1*                         p.P619S

Abbreviation: BD, bipolar disorder.

Annotations for the longest transcript.

Frameshift deletions directly introducing a stop codon.

###### New candidate genes for BD from whole-exome sequencing

  *Intolerant genes hit by* de novo *LOF mutations*                                                            
  --------------------------------------------------- ---- ------------- ------- ------- --------------------- ---
  *MACF1*                                              I    Frameshift   −3.92   0.21       Most intolerant     
  *UNC13B*                                             I    Splice site  −2.89   0.59     ![](mp201669i1.jpg)   
  *KMT2C*                                              I     Nonsense    −2.52   0.91                           
  *EHD1*                                               I     Nonsense    −1.38   4.39                           
  *XPO4*                                               II    Nonsense    −0.78   12.97                          
  *KLF4*                                               I    Frameshift   −0.45   24.19      Less intolerant     

  *Genes hit by* de novo *protein-altering mutations in BD and schizophrenia*                                              
  ----------------------------------------------------------------------------- ---- ------------ ------------ --- ------- --------
  *BZRAP1*                                                                       I     Inframe      Missense   2   0.130   0.0074
  *GLI3*                                                                         I     Missense     Missense   2   0.130   0.0075
  *DNAH9*                                                                        II    Missense    Frameshift  2   0.295   0.034
  *KMT2C*                                                                        I     Nonsense     Missense   2   0.299   0.035
  *MACF1*                                                                        I    Frameshift    Missense   2   0.355   0.048
                                                                                                                            

Abbreviations: BD, bipolar disorder, LOF, loss-of-function; RVIS, Residual Variation Intolerance Score.

Number of expected mutations were calculated by using per-gene mutation rates provided in Samocha *et al.*^[@bib49]^

*P*-values calculated by invoking Poisson distribution probabilities.

Lower RVIS and RVIS percentile indicate that the gene is less tolerant to protein-altering variants.

[^1]: These authors contributed equally to this work and are listed in alphabetical order.
